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Abstract
OBJECTIVE: To conduct a review of the systematic
reviews and meta-analyses on the Traditional Chi-
nese Medicine (TCM) treatment of type 2 diabetes
mellitus (T2DM).
METHODS: We searched PubMed, Cochrane, Web
of Science, Chinese Biomedical Literature Database
(CBM), China National Knowledge Infrastructure
(CNKI), China Science and Technology Journal Data-
base (VIP), Wanfang, and other databases from da-
tabase inception to May 2014 for systematic re-
views and meta-analyses on TCM treatment of
T2DM. Manuscripts were read by two investigators
if they met the inclusion criteria, and data were ex-
tracted. A Measurement Tool to Assess Systematic
Reviews (AMSTAR) was used to classify research
quality, and the evidence quality was graded by
the Grade of Recommendation, Assessment, Devel-
opment, and Evaluation (GRADE) system.
RESULTS: Eighteen systematic reviews and me-
ta-analyses were considered. Fifteen analyzed the
efficacy of Chinese herbal medicines, and three in-
vestigated the efficacy of acupuncture. AMSTAR
evaluation ranged from 3-10, and re-evaluation of
the main results implied that treatment of T2DM
with TCM has certain advantages when compared
with conventional Western medicine. However, the
evidence quality was generally low.
CONCLUSION: This work shows favorable evidence
for the clinical treatment of TCM on T2DM. Howev-
er, it is recommended that evidence-based deci-
sions are made based on clinical trials because of
the GRADE scores of the studies. To achieve high-
er quality of clinical research, clinical research on
TCM requires specific and suitable research meth-
ods. Further trials may increase the quality of evi-
dence to evaluate the clinical efficacy of TCM for
T2DM.
© 2016 JTCM. All rights reserved.
Key words: Medicine, Chinese traditional; Diabetes
Mellitus, type 2; Review; Meta-analysis
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a common disease
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with a complex etiology. World Health Organization
reported that in 2000 there were 151 million people
suffering from diabetes worldwide, and that an estimat-
ed 300 million people will suffer from diabetes in
2025.1,2 The current pace of development of diabetes
has far exceeded expectations. The prevalence of diabe-
tes and prediabetes among Chinese adults is 9.7% and
15.5% , respectively,3,4 up from less than 1% in 1980,
2.5% in 1994, and 5.5% in 2000. Diabetes is a risk fac-
tor for cardiovascular disease and stroke, which caused
29 million deaths by 2010.5,6 T2DM can cause a vari-
ety of complications if blood glucose levels are not con-
trolled, and results in the use of medications, high out-
patient and inpatient costs, and requires expensive diag-
nostic tests. Furthermore, absenteeism from recurrent
symptoms can cause indirect economic losses. Modern
treatment for T2DM is mainly via Western Medicine.
However, severe side-effects of medications make com-
plementary and alternative therapies more appealing
among patients and clinicians. These complementary
treatments include herbs, acupuncture, and other Tradi-
tional Chinese Medicine (TCM).7
A systematic review re-evaluates collected systematic
reviews on the treatment, diagnosis, and other aspects
of specific disease or health problems, and can provide
a higher quality of evidence for readers.8 Numerous sys-
tematic reviews and meta-analyses on TCM manage-
ment of T2DM have been published. However, the
methodological quality and limitations of individual
studies has resulted in a lack of quality evidence. There-
fore, this study aims to re-evaluate the systematic re-
views and meta-analyses, and classify their quality of
evidence using the Grade of Recommendation, As-
sessment, Development, and Evaluation (GRADE)
system.
MATERIALS ANDMETHODS
Search strategy
PubMed, Cochrane, Web of Science, Chinese Biomedi-
cal Literature Database (CBM), China National
Knowledge Infrastructure (CNKI), China Science and
Technology Journal Database (VIP), and Wanfang da-
tabases were searched on computer from database in-
ception to May 2014. The grey literature was also
searched using the CNKI and Wanfang doctor/master
thesis database. Different combinations of key words
and random words (Cochrane Library [MeSH],
PubMed [MeSH], CBM [MeSH]) were chosen based
on different databases. Meanwhile, the references at-
tached to the article or related reviews were tracked,
and interventions were excluded from the retrieval
strategy. Search terms included: type 2 diabetes melli-
tus, systematic reviews, and meta-analysis. The search
strategy was presented as follows, taking the Cochrane
Library as an example.
#1 Type 2 diabetes mellitus
#2 Type 2 diabetes mellitus [MeSH Terms]
#3 T2DM
#4 Meta-Analysis
#5 Meta-Analysis [MeSH Terms]
#6 Meta-Analysis [Publication Type]
#7 Systematic review
#8 #1 OR #2 OR #3
#9 #4 OR #5 OR #6 OR #7
#10 #8 AND #9
Inclusion criteria
(a) Systematic Review or meta-analysis on TCM treat-
ment for T2DM as a primary intervention with at least
one randomized controlled trial (RCT) either in Eng-
lish or Chinese. (b) The original study objects were pa-
tients with T2DM or in accordance with the relevant
domestic or overseas diagnostic criteria, not limited by
sex and ethnicity. (c) The interventions were mainly
TCM therapy, including herbal medicine (e. g. herb
compounds, single herb, Chinese patent medicine, or
herbal extracts), acupuncture (e. g. acupuncture, moxi-
bustion, acupoint injection, acupoint application, or
auricular acupuncture), and massage. (d) The latest or
the most detailed edition was chosen for repeatedly
published literature. (e) The grey literature like confer-
ence papers meeting the above criteria was considered.
Exclusion criteria
(a) Comparative studies on different Chinese medicine
therapies (e. g. Chinese herbal medicine vs acupunc-
ture or herb compounds vs Chinese patent medicine);
(b) quality assessment and methodological studies for
systematic reviews; and (c) abstracts or comments for
conference papers.
Literature screening and review data extraction
Two individual investigators read all titles and ab-
stracts, and research that was obviously in accordance
with the exclusion criteria was eliminated, while those
initially meeting the inclusion criteria were read in full.
Discrepancies were resolved by discussion or involve-
ment of the third investigator. Information extracted
from the review data included: title, author, source, ob-
ject of study, inclusion criteria, exclusion criteria, treat-
ment group interventions, control group interventions,
course of treatment, quality assessment methods, index-
es for therapeutic effects, and adverse events. After
completing the data extraction form, crosschecking
was executed between the two investigators.
Assessment of literature quality and evidence quality
The methodological quality of included systematic re-
views or meta-analyses was evaluated by A Measure-
ment Tool to Assess Systematic Reviews (AMSTAR).
The AMSTAR tables include 11 items, each with com-
ment options of "YES," "NO," "NOT CLEAR," or
"NOT USED." Each item with the answer "YES" is re-
corded as 1 point, while answers to the rest are record-
ed as 0 points, for a potential total of 11.9 The quality
556
JTCM |www. journaltcm. com
classification by AMSTAR scores is as follows: 0-4 is
low, 4-8 is medium, and 9-11 is high. The evidence
quality of the systematic reviews was assessed by
GRADE. Evidence classification is as follows: (a) high
quality (very confident that the real effects are close to
those estimated; (b) medium quality (medium confi-
dence that the real effects are close to those estimated);
(c) low quality (limited confidence that the real effects
are close to those estimated); and (d) very low quality
(almost no confidence that the real effects compare
with those estimated).
RESULTS
Literature search results
Eighty papers were searched after preliminary retrieval.
Ten repeated studies were excluded by literature man-
agement software (EndNote X6), while five did not
meet the inclusion criteria. Therefore, 65 papers were
initially included. After reading the full text of each pa-
per, the following were excluded: 15 systematic re-
views, three repeated conference papers/journal arti-
cles, three papers on literature quality assessment, five
papers on the systematic reviews or meta-analyses
whose interventions did not meet the exclusion crite-
ria, and one research comment. Finally, 18 papers were
included.10-27 There were six manuscripts published in
English,22-27 including one Cochrane review,26 and 12
Chinese manuscripts10-21 published from 2003 to 2013.
The literature screening procedure is shown in Figure 1.
Basic characteristics and quality assessment of
included literature
There were 15 systematic reviews and meta-analyses10,
12-20, 22, 23, 25-27 on the efficacy and safety of Chinese herbal
treatment for T2DM, among the 18 papers. The herb-
al medicines used included: (a) Chinese patent medi-
cines, including Liuweidihuang pills; (b) herbal ex-
tracts like berberine and green tea extracts; and (c)
point injection formulations (e. g. astragalus injection,
puerarin injection, and Shengmai injection). The re-
maining three papers11,21,24 evaluated the efficacy of acu-
puncture therapy on T2DM. Two papers11,21 assessed
the efficacy of point injection, and the final paper24
studied the efficacy of acupuncture. The methodologi-
cal quality of the studies was evaluated by AMSTAR,
with total points ranging from 3 to 10. Six papers were
October 15, 2016 |Volume 36 | Issue 5 |
Liu MJ et al. / Systematic Review
Figure 1 Literature screening procedure and results
CBM: Chinese Biomedical Literature Database; CNKI: China National Knowledge Infrastructure; VIP: China Science and Technology
Journal Database.
Obtain relative literature by searching
the databases (n = 80)
PubMed (n = 5), Cochrane (n = 10),
Web of Science (n=6),CNKI (n=21),
VIP (n = 11), Wanfang (n = 9),
CBM (n = 18)
Obtain relative literature by other
sources
(n = 0)
Exclude the repeated
literature
(n = 65)
Preliminary screening by
reading the tiles and
abstracts (n = 65)
Exclude (n = 30)
Non-research literature like journals items
(n = 6), column introduction (n = 5),
submission instructions (n = 8),
conference notices (n = 9), news reports
Not in accord with the inclusive criteria
(n = 2)Re-screening by reading
the full paper
(n = 35)
Exclude (n = 17)
Systematic review (n = 5)
Interventions not in accord with
the inclusive criteria (n = 5)
Comment paper about the
literature quality (n = 3)
Repeated conference paper and
journal published paper (n = 3)
Research comment (n = 1)
Incorporate qualitative
synthesized literature
(n = 18)
Incorporate quantitative
synthesized (Meta analysis)
literature (n = 18)
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classified as high quality and five as medium quality. In-
formation on the included studies is presented inTable 1.
Results of re-evaluation
Ten papers12-16,19-20,22-23,26 evaluated the efficacy and safety
of Chinese patent medicine treatment for T2DM.
There was one26 Cochrane systematic review. The re-
sults suggested some clinical efficacy of Chinese patent
medicine when compared with conventional Western
medicine or placebo treatment. However, the GRADE
classification ranged from low quality to very low quali-
ty, because of the low quality of eligible research. Three
papers14,15,22 assessed the efficacy of Liuweidihuang pills
in the treatment of T2DM compared with convention-
al Western medicine. The AMSTAR scores were 4, 4,
and 9, respectively. Meta-analysis showed superior effi-
cacy of Liuweidihuang pills for T2DM compared with
conventional Western Medicine. However, limitations
in the original research resulted in a GRADE classifica-
tion of low quality.
Three papers10,25,27 evaluated the clinical efficacy of herb-
al extracts (berberine and the green tea extracts) for
T2DM. The research to evaluate the clinical efficacy of
berberine was based on randomized double-blind place-
bo-controlled trials. The results showed that herbal
medicines have some clinical efficacy when compared
with placebo treatment. Despite the high methodologi-
cal quality, factors like small sample size and publica-
tion bias resulted in a GRADE classification of medi-
um quality. One systematic review27 included seven
clinical trials on using green tea extracts for T2DM.
Meta-analysis of the trials found that green tea extracts
were not significantly different in overall clinical effica-
cy and other indicators in patients when compared
with the placebo treatment.
Two systematic reviews11,21 analyzed the efficacy of as-
tragalus injection, puerarin injection, and Shengmai in-
jection treatment for T2DM2. Meta-analysis showed
that astragalus injection was clinically effective in
T2DM patients [RR = 1. 58, 95% CI (1. 20, 2. 09)]
when compared with the control group, and point in-
jection of puerarin was significantly better than the
control group [RR = 1. 28, 95% CI (1. 11, 1. 47)].
However, the GRADE classification was very low quali-
ty because of limitations, wide confidence intervals,
small sample size, and publication bias.
One systematic review on the treatment of T2DM by
acupunctures published by Tae-Hun Kim24 studied the
efficacy and safety of acupunctures therapy vs conven-
tional Western Medicine interventions. The meta-anal-
ysis suggested that acupuncture improved clinical effi-
cacy compared with conventional Western Medicine.
No severe side-effects were observed. However, the bias
risk for the original study resulted in a GRADE classifi-
cation of low quality.
DISCUSSION
This study found that there are certain clinical effects
that TCM treatment can exert on T2DM, and there
are few adverse reactions, such as hypoglycemia, when
compared with Western drugs alone. Furthermore,
treatment by Chinese medicine plus Western Medicine
was superior to that of Western Medicine alone.
T2DM is categorized as "Xiao Ke" in TCM, and was
first mentioned in the Chinese book Su Wen Qi Bing
Lun.28 An alternative name for "Xiao Ke" is described
in Huang Di Nei Jing29 as "Xiao Dan, " "Fei Xiao," or
"Ge Xiao" based on different pathogeneses and symp-
toms. TCM theorizes that the internal organs weak-
ness, excessive intake of fat and sugar, and mood disor-
ders are the main causes of "Xiao Ke" The pathogenesis
is based on body fluid loss dryness-heat, according to
TCM. Furthermore, a lack of Yin is its intrinsic factor,
while dryness-heat is its extrinsic factor. The most com-
monly evaluated drug among the Chinese patent drugs
was Liuweidihuang pills, which is composed of pre-
pared prepared Dihuang (Radix Rehmanniae), Shan-
zhuyu (Fructus Macrocarpii), Shanyao (Rhizoma Di-
oscoreae Oppositae), Zexie (Rhizoma Alismatis), Mudan-
pi (Cortex Moutan Radicis), Fuling（Poria）. The herbs
can help to improve liver and kidney function. In dia-
betes patients treated with Liuweidihuang pills for
12 weeks, fasting blood glucose and HbA1c concentra-
tions decreased, blood NO levels increased, endothelin
(ET) contents decreased, and superoxide dismutase
and glutathione peroxidase increased significantly the
treatment group than the control group patients.com-
pared with before intervention.30 These results suggest
that the use of Liuweidihuang pills in the early stages
of diabetes can help to reduce blood glucose levels, im-
prove oxidative stress, and recover NO-ET levels.
Therefore, it can protect injured endothelial cells and
prevent the subsequent macrovascular complications of
diabetes. We found that TCM has advantages in the
treatment of T2DM when compared with the clinical-
ly used drugs. However, the original research method-
ological limitations resulted in low GRADE classifica-
tions for quality of evidence and low credibility of the
assessment results. The relevant herbal extracts or herb-
al medicine compounds have attracted the attention of
global researchers because of developments in the for-
mulation and preparation, and the controllability of
clinical studies. Among them was berberine, which can
control blood glucose and improve diabetes symptoms
by improving the insulin resistance, inhibiting gluco-
neogenesis, and reducing cholesterol.31-33 Additional in-
vestigations that compare Western and Chinese medi-
cine are required to meet the development needs of the
next era.34
The eligible 18 systematic reviews and Meta-analyses
on the treatment of T2DM by TCM were published
between 2002 and 2013. There were 12 Chinese pa-
pers with AMSTAR from 3 to 10, and six English pa-
pers with AMSTAR from 5 to 10. The methodological
quality was relatively low for Chinese papers when
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compared with English papers, according to the
GRADE classifications. Numerous systematic evalua-
tions of Chinese medicine interventions have been per-
formed by Chinese researchers.35-37 The results generally
found that incomplete literature retrieval, poor control
of selection bias, and low accuracy of data combination
methods are present in Chinese papers, which affected
the credibility of the results. High quality of systematic
reviews and meta-analyses are one of the most impor-
tant sources of evidence for evidence-based medicine
practice, and are the best basis from which to make the
clinical decisions. The methodological quality of sys-
tematic reviews on TCM needs improvement, so
high-quality clinical studies with large prospective,
multi-center, double-blind and randomized designs
should be conducted.
Comprehensive literature retrieval and quality assess-
ment were strictly executed in this work, and the
GRADE classification system was used to classify the
evidence quality. However, there are some limitations
of our study. Most research trials were executed in Chi-
na, and the limitations of research design quality and
sample sizes affect the extrapolation and the strength of
evidence. Furthermore, stratified analysis of disease
course, syndromes, and complications were excluded
by the eligible research. Therefore, it is difficult to pre-
cisely evaluate the efficacy of TCM treatment for
T2DM.
In summary, the present study can act as a reference for
the clinical use of TCM for T2DM, but caution is ad-
vised for clinicians because of GRADE classifications
of the included studies. Nevertheless, this study can
engage researchers involved in evidence-based medi-
cine, statistical methods, and the clinical health field.
Professional research teams should be trained to ex-
plore the evaluation of TCM, and analyze the litera-
ture on the use of TCM in treatments. Meanwhile,
quality supervision on the systematic evaluation of
TCM should be carried out, and an evaluation method-
ology should be established along with a TCM litera-
ture database. This will ensure that TCM treatments
can be evaluated objectively, which will improve the
evidence quality of Chinese medicine evidence-based
health policy.
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